Mechanical thrombectomy with a novel device: initial clinical experience with the ANA thrombectomy device - 18/06/22
, David Hernandez a, Carlos Piñana a, Manuel Requena b, ⁎ , David S. Liebeskind c, Raul G. Nogueira d, Tudor Jovin e, Tommy Andersson f, g, Christoph Cognard h, Adnan Siddiqui i, Marc Ribo b Graphical abstract |
Highlights |
• | The ANA™ thrombectomy system is a novel device comprising a self-expanding funnel designed to reduce fragmentation by locally restricting flow. |
• | In in vitro phantom and swine models ANA™ device showed high recanalization rates with no safety concerns. |
• | In this first-in-human study, the ANA™ device achieved a high rate of complete reperfusion, sudden recanalization, and a good safety profile. |
Abstract |
Introduction |
The ANA™ (Anaconda Biomed) thrombectomy system is a novel stroke thrombectomy device comprising a self-expanding funnel designed to reduce clot fragmentation by locally restricting flow while becoming as wide as the lodging artery. Once deployed, ANA allows distal aspiration in combination with a stentretriever (SR) to mobilize the clot into the funnel where it remains copped during extraction. We investigate safety and efficacy of ANA™ in a first-in-man study.
Methods |
Prospective data was collected on 35 consecutive patients treated as first line with ANA™ at a single centre. Outcome measures included per-pass reperfusion scores, symptomatic intracerebral hemorrhage (sICH), NIHSS at day 5, and mRS at 90 days.
Results |
Median NIHSS was 12(9−18). Sites of primary occlusion were: 5 ICA, 15 M1-MCA, 15 M2-MCA. Primary performance endpoint, mTICI 2b-3 within 3 passes without rescue therapy was achieved in 91.4% (n = 32) of patients; rate of complete recanalization (mTICI 2c-3) was 65.7%. First pass complete recanalization rate was 42.9%, and median number of ANA passes 1(IQR: 1−2). In 17.1% (n = 6) rescue treatment was used; median number of rescue passes was 2(1–7), leading to a final mTICI2b-3rate of 94.3% (n = 33). There were no device related serious adverse events, and rate of sICH was 5.7% (n = 2). At 5 days median NIHSS was 1 (IQR 1−6) and 90 days mRS 0−2 was achieved in 60% of patients.
Conclusions |
In this initial clinical experience, the ANA™ device achieved a high rate of complete recanalization with a good safety profile and favourable 90 days clinical outcomes.
El texto completo de este artículo está disponible en PDF.Keywords : Mechanical thrombectomy, Stroke, New device
Esquema
Vol 49 - N° 4
P. 324-328 - juin 2022 Regresar al número
Artículo precedente
- Benefit of mechanical thrombectomy in acute ischemic stroke related to calcified cerebral embolus
- Téodor Grand, Cyril Dargazanli, Chrysanthi Papagiannaki, Agnetha Bruggeman, Christoph Maurer, Gregory Gascou, Cédric Fauche, Romain Bourcier, Guillaume Tessier, Raphaël Blanc, Malek Ben Machaa, Gaultier Marnat, Xavier Barreau, Julien Ognard, Jean-Christophe Gentric, Charlotte Barbier, Benjamin Gory, Christine Rodriguez, Grégoire Boulouis, François Eugène, Pierre Thouant, Frederic Ricolfi, Kevin Janot, Denis Herbreteau, Omer Faruk Eker, Matteo Cappucci, Tomas Dobrocky, Markus Möhlenbruch, Theo Demerath, Marios Psychogios, Sebastian Fischer, Alessandro Cianfoni, Charles Majoie, Bart Emmer, Henk Marquering, Rémi Valter, Stéphanie Lenck, Kévin Premat, Jonathan Cortese, Didier Dormont, Nader-Antoine Sourour, Eimad Shotar, Yves Samson, Frédéric Clarençon
- Transient modifications of the olfactory bulb on MR follow-up of COVID-19 patients with related olfactory dysfunction
- Amine Ammar, Lea Distinguin, Anaelle Chetrit, Dominique Safa, Stephane Hans, Robert Carlier, Jerome R. Lechien, Myriam Edjlali
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?